+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Phase 3
Age: 18Years +
All Genders
ID07413939

Study Comparing RO7771950 Versus Tucatinib With Trastuzumab and Capecitabine for Advanced HER2-Positive Breast Cancer

Led by Hoffmann-La Roche · Updated on 2026-10-06

650

Participants Needed

206

Research Sites

178 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effectiveness and safety of RO7771950 combined with trastuzumab and capecitabine compared to tucatinib with trastuzumab and capecitabine in people with locally advanced or metastatic HER2-positive breast cancer. This study includes patients with or without brain metastases and aims to provide new insights into treatments for this serious condition. The trial is a randomized, open-label study sponsored by Hoffmann-La Roche and involves multiple centers. Participants will be assigned to one of three groups two groups receive different doses of RO7771950 orally twice a day along with trastuzumab and capecitabine, while the third group receives tucatinib orally twice a day with the same combination of trastuzumab and capecitabine. Trastuzumab is given either intravenously or subcutaneously according to local guidelines, and capecitabine is taken orally twice daily. The study includes two parts and is designed to adapt as it progresses to ensure the best evaluation of treatments. During the trial, participants will be closely monitored through various assessments including imaging to measure tumor progression, quality of life evaluations, and safety checks such as heart function tests and monitoring of side effects. The main measure of success is progression-free survival over about 35 months. Other outcomes include overall survival, response rates, and symptom changes, with follow-ups continuing up to about 53 months. Participants will have regular visits for treatment and evaluations throughout the study period.

CONDITIONS

Brief Title

RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive

Research Team

R

Reference Study ID Number: WO46069 https://forpatients.roche.com/ No attachments to email below.

F

Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here